<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03744819</url>
  </required_header>
  <id_info>
    <org_study_id>IMRM2018</org_study_id>
    <nct_id>NCT03744819</nct_id>
  </id_info>
  <brief_title>Biomarkers for Prediction of Tumor Response to Radiotherapy</brief_title>
  <official_title>Exploration of Potential Biomarkers to Predict Tumor Response to Radiotherapy in Patients With Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chuangzhen Chen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shantou University Medical College</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to explore potential biomarkers for prediction of therapeutic outcomes in
      patients with solid tumors after radiotherapy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients pathologically confirmed with solid tumor that requires radiotherapy will be
      recruited to this study. All enrolled will have tumor biopsy at primary site and peripheral
      blood collection during the course of radiotherapy and when the disease progresses. These
      biological specimens will be used for exploration of potential biomarkers that could predict
      the tumor response and long-term outcome of patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 29, 2018</start_date>
  <completion_date type="Anticipated">November 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Gene signature changes</measure>
    <time_frame>From the date of enrollment until the date of disease progression, assessed up to 3 years</time_frame>
    <description>Changes of Expression level of signature genes in patients' biological specimens</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease-specific survival</measure>
    <time_frame>up to 3 years of follow-up</time_frame>
    <description>The tumor disease-specific survival of patients</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Overall survival</measure>
    <time_frame>up to 3 years of follow-up</time_frame>
    <description>The overall survival of patients</description>
  </other_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Solid Tumors</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Tumor samples and peripheral blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients proven diagnosis of solid tumors and will have radiotherapy as part of their
        therapeutic regimens in Cancer Hospital of Shantou University Medical College
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathological proven diagnosis of solid tumors

          -  Tumor accessible for biopsy during the course of radiotherapy

          -  Patient must provide study-specific informed consent prior to study entry

        Exclusion Criteria:

          -  History of autoimmune diseases

          -  History of immunotherapy

          -  Prior radiation therapy that would result in overlap of planned radiation therapy
             fields

          -  Will receive immunotherapy during the course of radiotherapy

          -  Contraindications for biopsy, such as high bleeding risk
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chuangzhen Chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Hospital of Shantou University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chuangzhen Chen, MD</last_name>
    <phone>+86 13923995569</phone>
    <email>stccz@139.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cancer Hospital, Shantou University Medical College</name>
      <address>
        <city>Shantou</city>
        <state>Guangdong</state>
        <zip>515031</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chuangzhen Chen, MD</last_name>
      <phone>86-13923995569</phone>
      <email>stccz@139.com</email>
    </contact>
    <contact_backup>
      <last_name>Jianzhou Chen, MD</last_name>
      <phone>86-13417049908</phone>
      <email>cjzeoeo@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Chuangzhen Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>November 4, 2018</study_first_submitted>
  <study_first_submitted_qc>November 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2018</study_first_posted>
  <last_update_submitted>November 15, 2018</last_update_submitted>
  <last_update_submitted_qc>November 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Shantou University Medical College</investigator_affiliation>
    <investigator_full_name>Chuangzhen Chen</investigator_full_name>
    <investigator_title>Deputy Director, Department of Radiation Oncology</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

